HER2 overexpression correlates with survival after curative resection of pancreatic cancer

Cancer Science

Volumn 100, Issue 7, 2009, Pages 1243-1247

  Komoto, Masahiro ^a   Nakata, Bunzo ^a   Amano, Ryosuke ^a   Yamada, Nobuya ^a   Yashiro, Msakazu ^a   Ohira, Masaichi ^a   Wakasa, Kenichi ^b   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 RABBIT POLYCLONAL ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67449089653     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01176.x     Document Type: Article

References (25)

1. Coussens L, Yang-Feng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-9.
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Eng J Med 2008; 358: 1160-74.
3. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results. Invest New Drugs 1999; 17: 259-69.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the Her2/neu oncogene. Science 1987; 235: 177-82.
5. Slamon DJ, Godolphin W, Jones LA et al. Studies of the Her2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
6. Alberton DG, Collins C, McComick Gray JW. Chromosome aberrations in solid tumors. Nat Genet 2003; 34: 369-76.
7. Wang S, Saboorian HM, Frenkel EP et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 2002; 15: 137-45.
8. Edgerton SM, Moore D 2nd, Merkel D, Thor AD. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morph 2003; 11: 214-21.
9. Kern JA, Schwartz DA, Nordberg JE et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184-91.
10. Jaehne J, Urmacher C, Thaler HT, Friedlander-Klar H, Cordon-Cardo C, Meyer HJ. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118: 474-9.
11. Park DII, Yun JW, Park JH et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-9.
12. Lei S, Appert HE, Nakata B, Domenico DR, Kim K, Howard JM. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol 1995; 17: 15-21.
13. Yamanaka Y, Friess H, Kobrin MS et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 1993; 24: 1127-34.
14. Koka V, Potti A, Koch M, Fraiman G, Mehdi S, Levitt R. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. Anticancer Res 2002; 22: 1593-7.
15. Sobin LH, Witterkind C, eds. TNM. Classification of Malignant Tumors, 6th edn. New York: Wiley-Liss, 2002: 93-6.
16. Day JD, Digiuseppe JA, Yeo C et al. Immunohistochemical evaluation of HER-2/new expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996; 27: 119-24.
17. Saxby AJ, Nielsen A, Scarlett CJ et al. Assessment of HER-2 status in pancreatic adenocarcinoma: Correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 2005; 29: 1125-34.
18. Mass RD, Press MF, Anderson S et al. Evaluation of clinical outcomes according to Her2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6: 240-6.
19. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-30.
20. Stoecklein NH, Luebke AM, Erbersdobler A et al. Copy number of chromosome 17 but not her2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol 2004; 22: 4737-45.
21. Vogel CL, Cobleign MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2 overexpression metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
22. Kimura K, Sawada T, Komatsu M et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 2006; 12: 4925-32.
23. Safran H, Iannitti D, Ramanathan R et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004; 22: 706-12.
24. Rusnak DW, Lackey K, Affleck K et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
25. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER-2-positive advanced breast cancer. N Eng J Med 2006; 355: 2733-43.